Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence
Open Access
- 4 August 2016
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (8) , e0159727
Abstract
Cryptococcal meningitis (CM) is a leading cause of HIV-associated mortality. In clinical trials evaluating treatments for CM, biomarkers of early fungicidal activity (EFA) in cerebrospinal fluid (CSF) have been proposed as candidate surrogate endpoints for all- cause mortality (ACM). However, there has been no systematic evaluation of the group-level or trial-level evidence for EFA as a candidate surrogate endpoint for ACM. We conducted a systematic review of randomized trials in treatment of CM to evaluate available evidence for EFA measured as culture negativity at 2 weeks/10 weeks and slope of EFA as candidate surrogate endpoints for ACM. We performed sensitivity analysis on superiority trials and high quality trials as determined by Cochrane measures of trial bias. Twenty-seven trials including 2854 patients met inclusion criteria. Mean ACM was 15.8% at 2 weeks and 27.0% at 10 weeks with no overall significant difference between test and control groups. There was a statistically significant group-level correlation between average EFA and ACM at 10 weeks but not at 2 weeks. There was also no statistically significant group-level correlation between CFU culture negativity at 2weeks/10weeks or average EFA slope at 10 weeks. A statistically significant trial-level correlation was identified between EFA slope and ACM at 2 weeks, but is likely misleading, as there was no treatment effect on ACM. Mortality remains high in short time periods in CM clinical trials. Using published data and Institute of Medicine criteria, evidence for use of EFA as a surrogate endpoint for ACM is insufficient and could provide misleading results from clinical trials. ACM should be used as a primary endpoint evaluating treatments for cryptococcal meningitis.Keywords
Funding Information
- Division of Intramural Research (AI001123)
- Division of Intramural Research (AI001124)
This publication has 47 references indexed in Scilit:
- Epidemiology of Cryptococcal Meningitis in the US: 1997–2009PLOS ONE, 2013
- Biomarkers and surrogate endpoints in clinical trialsStatistics in Medicine, 2012
- Prognosis and management of cryptococcal meningitis in patients with human immunodeficiency virus infectionNeurobehavioral HIV Medicine, 2012
- Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitisAIDS, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in MalawiClinical Infectious Diseases, 2010
- Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 PatientsClinical Infectious Diseases, 2009
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six WeeksNew England Journal of Medicine, 1987
- A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal MeningitisNew England Journal of Medicine, 1979